Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.62 |
| ▸ | FNTA | P49354 | 3/20 | 0.60 |
| ▸ | FNTB | P49356 | 3/20 | 0.60 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14151882 | 0.98 | GGPS1 (0.61) | KMT2AGGPS1FNTAFNTB | |
| SCHEMBL14151883 | 0.98 | GGPS1 (0.61) | KMT2AGGPS1FNTAFNTB | |
| Squalene SCHEMBL28409601 | 0.87 | KMT2A (0.77) | KMT2AGGPS1 | |
| Squalene SCHEMBL27745343 | 0.87 | KMT2A (0.77) | KMT2AGGPS1 | |
| Squalene SCHEMBL27769242 | 0.87 | KMT2A (0.77) | KMT2AGGPS1 | |
| Squalene SCHEMBL27745351 | 0.87 | KMT2A (0.77) | KMT2AGGPS1 | |
| SCHEMBL23787698 | 0.86 | BTN3A1 (0.62) | KMT2AGGPS1FNTAFNTBPGGT1B | |
| SCHEMBL9061139 | 0.86 | FNTA (0.64) | KMT2AGGPS1FNTAFNTBPGGT1B | |
| SCHEMBL2455947 | 0.86 | FNTA (0.64) | KMT2AGGPS1FNTAFNTBPGGT1B | |
| SCHEMBL9061131 | 0.86 | FNTA (0.64) | KMT2AGGPS1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | claimed |
| US-20210046064-A1 | Treatment of Neurodegenerative Conditions by Disruption of Rhes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-18 | — | — | US | claimed |
| US-10864206-B2 | Treatment of neurodegenerative conditions by disruption of Rhes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-15 | — | — | US | claimed |
| US-20190083480-A1 | Treatment of Neurodegenerative Conditions by Disruption of Rhes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-21 | — | — | US | claimed |
| WO-2018132791-A1 | TREATMENT OF NEURODEGENERATIVE CONDITIONS BY DISRUPTION OF RHES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | WO | claimed |
| CN-119816589-A | Methods of improving cell therapies using organelle complexes | 国立大学法人北海道大学 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024085805-A1 | METHOD OF TREATING ADULT-ONSET AUTOSOMAL DOMINANT LEUKODYSTROPHY (ADLD) | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-04-25 | — | — | WO | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11839658-B2 | Aminoglycoside derivatives and nano-assemblies thereof, including those with quorum sensing inhibitory function | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-12-12 | — | — | US | disclosed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20160008374-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2016-01-14 | — | — | US | disclosed |
| WO-2016007765-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20150306281-A1 | DEVICES AND METHODS FOR INHIBITING STENOSIS, OBSTRUCTION, OR CALCIFICATION OF A NATIVE HEART VALVE, STENTED HEART VALVE OR BIOPROSTHESIS | CONCIEVALVE, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2091323-A2 | PESTICIDAL AGGREGATES | Innovaform Technologies, LLC (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008076807-A2 | PESTICIDAL AGGREGATES | INNOVAFORM TECHNOLOGIES, LLC (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20040167102-A1 | Isoprenoid analog compounds and methods of making and use thereof | UNIVERSITY OF IOWA RESEARCH FOUNDATION. | 2004-08-26 | — | — | US | disclosed |
| US-6727234-B2 | FOR BLOCKING PRENYLATION TRANSFERASE ENZYMES; ANTICANCER AGENTS; STABILITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2004-04-27 | — | — | US | disclosed |
| US-20030022869-A1 | Isoprenoid analog compounds and methods of making and use thereof | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | KMT2A 4666/4885GGPS1 1007/4885FNTA 874/4885 |
| US-20030022869-A1 | Isoprenoid analog compounds and methods of making and use thereof | FNTA, RCE1, GGPS1 | KMT2A 4228/4885GGPS1 3/4885FNTA 1/4885 |
| US-20160008374-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | KMT2A 2213/4885GGPS1 3304/4885FNTA 3930/4885 |
| US-11839658-B2 | Aminoglycoside derivatives and nano-assemblies thereof, including those with quorum sensing inhibitory function | FNTA, FNTB, FDPS | KMT2A 4245/4885GGPS1 9/4885FNTA 1/4885 |
| US-20040167102-A1 | Isoprenoid analog compounds and methods of making and use thereof | FNTA, RCE1, GGPS1 | KMT2A 4228/4885GGPS1 3/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.